TY - JOUR
T1 - Comparison of Patient-Reported Care Satisfaction, Quality of Warfarin Therapy, and Outcomes of Atrial Fibrillation
T2 - Findings From the ORBIT-AF Registry
AU - Perino, Alexander C.
AU - Shrader, Peter
AU - Turakhia, Mintu P.
AU - Ansell, Jack E.
AU - Gersh, Bernard J.
AU - Fonarow, Gregg C.
AU - Go, Alan S.
AU - Kaiser, Daniel W.
AU - Hylek, Elaine M.
AU - Kowey, Peter R.
AU - Singer, Daniel E.
AU - Thomas, Laine
AU - Steinberg, Benjamin A.
AU - Peterson, Eric D.
AU - Piccini, Jonathan P.
AU - Mahaffey, Kenneth W.
N1 - Funding Information:
Turakhia receives research grants from Janssen, Medtronic Inc., AstraZeneca, Veterans Health Administration, and Cardiva Medical Inc; research support from AliveCor Inc., Amazon, Zipline Medical Inc., iBeat Inc., and iRhythm Technologies Inc.; and honoraria from Abbott, Medtronic Inc., Boehringer Ingel-heim, Precision Health Economics, iBeat Inc., Akebia, Cardiva Medical Inc., and Medscape/theheart.org. Gersh serves as a consultant for Janssen, Cipla Limited Data Safety Monitoring Board for Mount Sinai St. Lukes, Boston Scientific, Teva Pharmaceutical Industries, St. Jude Medical, Baxter Healthcare Corporation, Thrombosis Research Institute, Duke Clinical Research Institute, Duke University, Kowa Research Institute, and the Cardiovascular Research Foundation. Fonarow serves as a consultant for Janssen. Go receives research support from Johnson & Johnson. Hylek receives honoraria from Boehringer Ingelheim and Bayer and serves as a consultant for Daiichi Sankyo, Ortho-McNeil-Janssen, Johnson & Johnson, Boehringer Ingelheim, and Bristol-Myers Squibb. Kowey serves as a consultant for Johnson & Johnson, Daiich-Sankyo, Bristol-Myers Squibb, and Boehringer Ingelheim. Singer receives research support from Daiichi Sankyo and serves as a consultant for
Funding Information:
Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Johnson & Johnson, Merck, Bayer Healthcare, Pfizer, and Sanofi-Aventis. Thomas receives research support form Novartis, Boston Scientific, Gilead Sciences Inc., and Janssen. Steinberg receives research support from Boston Scientific and Janssen and serves as a consultant for Biosense-Webster. Peterson receives research support from Janssen and Eli Lilly and serves as a consultant for Janssen and Boehringer Ingelheim. Piccini receives research support from Abbott, ARCA biopharma, Boston Scientific, Gilead, Janssen, and Verily. Mahaffey receives research support from Abbott, Afferent, Amgen, Apple Inc., AstraZeneca, Cardiva Medical Inc., Daiichi, Ferring, Johnson & Johnson, Luitpold, Medtronic, Merck, NIH, Novartis, Sanofi, Tenax, and Verily and serves as a consultant for Abbott, Ablynx, AstraZeneca, Baim Institute, Boehringer Ingelheim, Bristol Myers Squibb, Elsevier, Glaxo Smith Kline, Johnson & Johnson, Medergy, Medscape, Mitsubishi, Myokardia, National Institutes of Health, Novartis, Novo Nordisk, Portola, Radiometer, Regeneron, Springer Publishing, and University of California, San Francisco. The remaining authors have no disclosures to report.
Publisher Copyright:
© 2019 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.
PY - 2019/5/7
Y1 - 2019/5/7
N2 - Background: Patient satisfaction with therapy is an important metric of care quality and has been associated with greater medication persistence. We evaluated the association of patient satisfaction with warfarin therapy to other metrics of anticoagulation care quality and clinical outcomes among patients with atrial fibrillation (AF). Methods and Results: Using data from the ORBIT-AF (Outcomes Registry for Better Informed Treatment of Atrial Fibrillation) registry, patients were identified with AF who were taking warfarin and had completed an Anti-Clot Treatment Scale (ACTS) questionnaire, a validated metric of patient-reported burden and benefit of oral anticoagulation. Multivariate regressions were used to determine association of ACTS burden and benefit scores with time in therapeutic international normalized ratio range (TTR; both ≥75% and ≥60%), warfarin discontinuation, and clinical outcomes (death, stroke, major bleed, and all-cause hospitalization). Among 1514 patients with AF on warfarin therapy (75±10 years; 42% women; CHA2DS2-VASc 3.9±1.7), those most burdened with warfarin therapy were younger and more likely to be women, have paroxysmal AF, and to be treated with antiarrhythmic drugs. After adjustment for covariates, ACTS burden scores were independent of TTR (TTR ≥75%: odds ratio, 1.01 [95% CI, 0.99–1.03]; TTR ≥60%: odds ratio, 1.01 [95% CI, 0.98–1.05]), warfarin discontinuation (odds ratio, 0.99; 95% CI, 0.97–1.01), or clinical outcomes. ACTS benefit scores were also not associated with TTR, warfarin discontinuation, or clinical outcomes. Conclusions: In a large registry of patients with AF taking warfarin, ACTS scores provided independent information beyond other traditional metrics of oral anticoagulation care quality and identified patient groups at high risk for dissatisfaction with warfarin therapy.
AB - Background: Patient satisfaction with therapy is an important metric of care quality and has been associated with greater medication persistence. We evaluated the association of patient satisfaction with warfarin therapy to other metrics of anticoagulation care quality and clinical outcomes among patients with atrial fibrillation (AF). Methods and Results: Using data from the ORBIT-AF (Outcomes Registry for Better Informed Treatment of Atrial Fibrillation) registry, patients were identified with AF who were taking warfarin and had completed an Anti-Clot Treatment Scale (ACTS) questionnaire, a validated metric of patient-reported burden and benefit of oral anticoagulation. Multivariate regressions were used to determine association of ACTS burden and benefit scores with time in therapeutic international normalized ratio range (TTR; both ≥75% and ≥60%), warfarin discontinuation, and clinical outcomes (death, stroke, major bleed, and all-cause hospitalization). Among 1514 patients with AF on warfarin therapy (75±10 years; 42% women; CHA2DS2-VASc 3.9±1.7), those most burdened with warfarin therapy were younger and more likely to be women, have paroxysmal AF, and to be treated with antiarrhythmic drugs. After adjustment for covariates, ACTS burden scores were independent of TTR (TTR ≥75%: odds ratio, 1.01 [95% CI, 0.99–1.03]; TTR ≥60%: odds ratio, 1.01 [95% CI, 0.98–1.05]), warfarin discontinuation (odds ratio, 0.99; 95% CI, 0.97–1.01), or clinical outcomes. ACTS benefit scores were also not associated with TTR, warfarin discontinuation, or clinical outcomes. Conclusions: In a large registry of patients with AF taking warfarin, ACTS scores provided independent information beyond other traditional metrics of oral anticoagulation care quality and identified patient groups at high risk for dissatisfaction with warfarin therapy.
KW - anticoagulation
KW - atrial fibrillation
KW - patient-centered care
KW - patient-reported outcome
KW - warfarin
UR - http://www.scopus.com/inward/record.url?scp=85065292812&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85065292812&partnerID=8YFLogxK
U2 - 10.1161/JAHA.118.011205
DO - 10.1161/JAHA.118.011205
M3 - Article
C2 - 31023126
AN - SCOPUS:85065292812
SN - 2047-9980
VL - 8
JO - Journal of the American Heart Association
JF - Journal of the American Heart Association
IS - 9
M1 - e011205
ER -